Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$17.30 -0.2%	$15.60	$9.50 ▼ $18.85	$1.57B	1.6	1.24 million shs	823,396 shs
CEMI Chembio Diagnostics	$0.46	$0.43	$0.19 ▼ $1.24	$16.71M	1.85	661,416 shs	351,642 shs
OASM Oasmia Pharmaceutical AB (publ)	$0.02	$1.46	$0.94 ▼ $5.70	$1.50M	0.96	98,414 shs	N/A
SESN Sesen Bio		$10.50	$0.37 ▼ $12.58	$2.56B	0.83	1.07 million shs	93,330 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	-0.17%	+8.19%	+0.46%	+22.09%	+63.98%
CEMI Chembio Diagnostics	0.00%	0.00%	0.00%	0.00%	+1.11%
OASM Oasmia Pharmaceutical AB (publ)	0.00%	0.00%	0.00%	0.00%	-60.00%
SESN Sesen Bio	0.00%	0.00%	0.00%	0.00%	0.00%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	3.1737 of 5 stars	4.5	2.0	0.0	0.0	3.2	1.7	0.6
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SESN Sesen Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$22.57	30.47% Upside
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A
SESN Sesen Bio	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest SESN, CEMI, AVDL, and OASM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2024	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
3/5/2024	AVDL Avadel Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
3/5/2024	AVDL Avadel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$18.00 ➝ $23.00
3/5/2024	AVDL Avadel Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$27.00 ➝ $29.00
3/5/2024	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $25.00
3/5/2024	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
2/6/2024	AVDL Avadel Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$27.96M	56.05	N/A	N/A	$0.98 per share	17.65
CEMI Chembio Diagnostics	$48.34M	0.35	N/A	N/A	$0.48 per share	0.95
OASM Oasmia Pharmaceutical AB (publ)	$220K	6.82	N/A	N/A	$0.63 per share	0.03
SESN Sesen Bio	$40M	0.00	N/A	3.39	$0.78 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$160.28M	-$2.04	N/A	20.84	N/A	N/A	-198.06%	-84.51%	5/2/2024 (Estimated)
CEMI Chembio Diagnostics	-$23.29M	-$1.20	N/A	∞	N/A	-47.03%	-113.57%	-38.22%	N/A
OASM Oasmia Pharmaceutical AB (publ)	-$18.95M	N/A	0.00	∞	N/A	-8,633.64%	-43.94%	-28.92%	N/A
SESN Sesen Bio	-$19.88M	-$0.10	N/A	N/A	N/A	N/A	6.70%	5.41%	N/A

Latest SESN, CEMI, AVDL, and OASM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/4/2024	Q4 2023	AVDL Avadel Pharmaceuticals	-$0.28	-$0.32	-$0.04	-$0.29	$17.41 million	$19.45 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A
SESN Sesen Bio	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	3.64	3.36
CEMI Chembio Diagnostics	N/A	1.23	1.04
OASM Oasmia Pharmaceutical AB (publ)	N/A	0.80	0.73
SESN Sesen Bio	N/A	6.10	6.10

Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
CEMI Chembio Diagnostics	8.65%
OASM Oasmia Pharmaceutical AB (publ)	0.11%
SESN Sesen Bio	16.45%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	4.00%
CEMI Chembio Diagnostics	3.30%
OASM Oasmia Pharmaceutical AB (publ)	N/A
SESN Sesen Bio	3.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	154	90.58 million	86.95 million	Optionable
CEMI Chembio Diagnostics	337	36.73 million	35.51 million	Not Optionable
OASM Oasmia Pharmaceutical AB (publ)	57	74.97 million	N/A	Not Optionable
SESN Sesen Bio	35	203.49 million	196.98 million	Optionable

SESN, CEMI, AVDL, and OASM Headlines

Source	Headline
	Trey Mewes startribune.com - April 10 at 12:53 AM
	Devin Haney: biography, record, fights and more espn.com - December 9 at 5:50 PM
	Tyson Fury: Biography, record, fights and more espn.com - December 2 at 10:49 AM
	Why the Tucker Carlson Biography Sales Are So Pathetic thedailybeast.com - September 13 at 10:23 PM
	Sesen Bio (NASDAQ: SESN) fool.com - August 4 at 6:23 PM
	James McTeigue Biography & Movies tribute.ca - May 10 at 6:46 PM
	After revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen Bio bizjournals.com - March 6 at 7:17 PM
	Sesen Bio wins shareholder approval for Carisma merger msn.com - March 2 at 1:30 PM
	Sesen Bio Stockholders Approve Merger with Carisma Therapeutics finance.yahoo.com - March 2 at 1:30 PM
	Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results finance.yahoo.com - February 28 at 12:42 PM
	SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigations benzinga.com - February 24 at 9:19 PM
	Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With Carisma finance.yahoo.com - February 21 at 10:50 AM
	BML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics stockhouse.com - February 17 at 8:59 PM
	Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting businesswire.com - February 16 at 4:47 PM
	Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger finance.yahoo.com - February 16 at 9:10 AM
	Sesen Bio reaches deal with investor group, paving way for Carisma merger endpts.com - February 15 at 2:11 PM
	Latest terms of Sesen Bio and Carisma merger appear to pass muster thepharmaletter.com - February 15 at 2:11 PM
	5 big dividend moves: Group 1 Automotive hikes by 20% \| Pro Recap finance.yahoo.com - February 15 at 9:11 AM
	BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics finance.yahoo.com - February 15 at 9:11 AM
	Sesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor group bizjournals.com - February 14 at 2:01 PM
	Sesen gains 11% on amended terms for merger with Carisma msn.com - February 14 at 9:00 AM
	Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger finance.yahoo.com - February 14 at 9:00 AM
	Sesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years ago finance.yahoo.com - February 6 at 10:17 AM
	Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger finance.yahoo.com - February 2 at 7:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Avadel Pharmaceuticals

NASDAQ:AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Chembio Diagnostics

NASDAQ:CEMI

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Oasmia Pharmaceutical AB (publ)

NASDAQ:OASM

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Sesen Bio

NASDAQ:SESN

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial